PulseAugur
LIVE 06:49:25
significant · [2 sources] · · 中文(ZH) 受美国拖欠会费等因素影响，世贸组织计划削减10%预算
0
significant

FDA approves Pfizer and Arvinas' new breast cancer drug VEPPANU

By PulseAugur Editorial · Summary by gemini-2.5-flash-lite from 2 sources

The World Trade Organization (WTO) is planning a 10% budget cut due to member states, including the United States, failing to pay their dues. This financial strain may lead to hiring freezes and the reduction of short-term staff. Separately, the U.S. Food and Drug Administration (FDA) has approved VEPPANU (vepdegestrant), a novel PROTAC therapy developed by Arvinas and Pfizer, for treating specific types of advanced or metastatic breast cancer. AI

Summary written by gemini-2.5-flash-lite from 2 sources. How we write summaries →

RANK_REASON Significant policy change at an international organization and a notable drug approval.

Read on 36氪 (36Kr) →

COVERAGE [2]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    WTO plans to cut budget by 10% due to factors such as US arrears

    当地时间5月1日获悉，一份世界贸易组织（WTO）的文件显示，鉴于美国再次陷入会费拖欠状态，且越来越多的成员国未能按时缴纳会费，世界贸易组织正准备削减约10%的支出，相关措施包括冻结招聘及裁减短期工作人员。根据WTO预算、财务与行政委员会3月12日和2月18日的内部文件显示， 美国目前属于10个“第一类拖欠”成员之一，这意味着其已拖欠会费至少一年但未满两年，进一步加剧了WTO日益沉重的财政压力。目前尚不清楚美国何时以及是否会支付这笔款项。（央视新闻）

  2. 36氪 (36Kr) TIER_1 中文(ZH) ·

    Pfizer and Arvinas's new breast cancer drug approved by US FDA

    当地时间5月1日，Arvinas公司与其合作伙伴辉瑞共同宣布，美国食品药品监督管理局（FDA）已批准VEPPANU （vepdegestrant）用于治疗经FDA授权检测确定的、雌激素受体阳性（ER+）/人表皮生长因子受体2阴性（HER2-）、雌激素受体1（ESR1）突变晚期或转移性乳腺癌成年患者，且患者需在接受至少一种内分泌治疗后出现疾病进展。这也是FDA首次批准一种蛋白降解靶向嵌合体（PROTAC），即一种异双功能蛋白质降解剂疗法。（界面）

RELATED ENTITIES

RELATED TOPICS